12 research outputs found

    Preformed CD40L Is Stored in Th1, Th2, Th17, and T Follicular Helper Cells as Well as CD4+8βˆ’ Thymocytes and Invariant NKT Cells but Not in Treg Cells

    Get PDF
    CD40L is essential for the development of adaptive immune responses. It is generally thought that CD40L expression in CD4+ T cells is regulated transcriptionally and made from new mRNA following antigen recognition. However, imaging studies show that the majority of cognate interactions between effector CD4+ T cells and APCs in vivo are too short to allow de novo CD40L synthesis. We previously showed that Th1 effector and memory cells store preformed CD40L (pCD40L) in lysosomal compartments and mobilize it onto the plasma membrane immediately after antigenic stimulation, suggesting that primed CD4+ T cells may use pCD40L to activate APCs during brief encounters. Indeed, our recent study showed that pCD40L is sufficient to mediate selective activation of cognate B cells and trigger DC activation in vitro. In this study, we show that pCD40L is present in Th1 and follicular helper T cells developed during infection with lymphocytic choriomeningitis virus, Th2 cells in the airway of asthmatic mice, and Th17 cells from the CNS of animals with experimental autoimmune encephalitis (EAE). pCD40L is nearly absent in both natural and induced Treg cells, even in the presence of intense inflammation such as occurs in EAE. We also found pCD40L expression in CD4 single positive thymocytes and invariant NKT cells. Together, these results suggest that pCD40L may function in T cell development as well as an unexpectedly broad spectrum of innate and adaptive immune responses, while its expression in Treg cells is repressed to avoid compromising their suppressive activity

    Severe inflammation does not compromise the lack of expression of pCD40L by Treg cells.

    No full text
    <p>CNS infiltrating leukocytes and splenocytes were obtained from EAE animals induced as <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0031296#pone-0031296-g005" target="_blank">Fig. 5<i>A</i></a>. <i>A</i>, Gating strategy for cells from CNS and spleen. <i>B & C</i>, Intracellular CD40L levels for effector CD4<sup>+</sup> T cells (<i>B</i>) and Treg cells (<i>C</i>). Data are representative of two independent experiments.</p

    In vivo-generated Th17 and Th17/Th1 cells store and mobilize pCD40L.

    No full text
    <p><i>A</i>, CNS infiltrating leukocytes were obtained from brains and spinal cords of EAE animals induced by immunization with CFA plus MOG peptide and pertussis toxin. <i>B</i>, CNS infiltrating leukocytes were analyzed by the CD40L mobilization assay followed by intracellular cytokine staining. <i>C</i>, Intracellular staining of IL-17A and IFN-Ξ³ in CNS CD4<sup>+</sup> T cells. <i>D</i>, CD40L mobilization in Th1 (IL-17A<sup>βˆ’</sup>IFN-Ξ³<sup>+</sup>), Th17 (IL-17A<sup>+</sup>IFN-Ξ³<sup>βˆ’</sup>), Th17/Th1 (IL-17A<sup>+</sup>IFN-Ξ³<sup>+</sup>), and antigen non-specific (IL-17A<sup>βˆ’</sup>IFN-Ξ³<sup>βˆ’</sup>) CD4<sup>+</sup> T cells upon antigenic stimulation. Data are representative of three independent experiments.</p

    In vitro-generated Th1 and Th17, but not Th2 or iTreg cells mobilize pCD40L.

    No full text
    <p><i>A</i> and <i>B</i>, Mobilization assay. In vitro-generated Th1, Th2, Th17, and iTreg cells were stimulated with PMA plus ionomycin or left unstimulated in the presence of PE-isotype Ab, PE-anti-CD40L or PE-anti-CTLA-4 at 37Β°C for 30 minutes. The levels of CD40L (<i>A</i>) and CTLA-4 (<i>B</i>) are shown. <i>C</i> and <i>D</i>, Intracellular staining. Cells were fixed without stimulation, permeabilized, and stained with PE-isotype Ab, PE-anti-CD40L or PE-anti-CTLA-4. The levels of CD40L (<i>C</i>) and CTLA-4 (<i>D</i>) are shown. Data are representative of five independent experiments.</p

    Excess IL-4 downregulates pCD40L levels in Th2 cells generated in vitro.

    No full text
    <p>Recovery of pCD40L in Th2 cells by neutralizing IL-4. <i>A–C</i>, Differentiated Th2 cells from 4get/DO11.10 spleen cells were restimulated with peptide-pulsed splenic APCs alone (Th2 2Β°) or in the presence of exogenous IL-4 (Th2 2Β° plus IL-4) or anti-IL-4 (Th2 2Β° plus anti-IL-4) for 4 days. <i>A</i>, The levels of IL-4/eGFP in each group of Th2 cells as well as Th1 negative control cells. <i>B</i>, IL-4 production upon PMA plus ionomycin stimulation by each group of Th2 cells was analyzed by ELISA. Each bar represents the mean Β± standard deviation for triplicates. <i>C</i>, Mobilization of pCD40L by each group of Th2 cells in response to PMA plus ionomycin. Data are representative of two independent experiments.</p

    In vivo-generated Th2 cells store and mobilize pCD40L.

    No full text
    <p><i>A</i>, BALB/c mice that had received 4get/DO11.10 CD4<sup>+</sup> T cells were subcutaneously immunized with papain plus OVA protein. Seven days later, cells from dLNs were analyzed by the mobilization assay. <i>B</i>, Gating strategy for antigen-specific IL-4/eGFP<sup>+</sup> DO11.10 cells (CD4<sup>+</sup>IL-4/eGFP<sup>+</sup>KJ1-26<sup>+</sup>). <i>C</i>, Mobilization of pCD40L by IL-4/eGFP<sup>+</sup> DO11.10 cells in response to PMA plus ionomycin or OVA peptide-pulsed APC. <i>D</i>, Those cells were further differentiated as T<sub>FH</sub> (CXCR5<sup>hi</sup>PD-1<sup>hi</sup>) and Th2 (CXCR5<sup>low</sup>PD-1<sup>low</sup>) cells. <i>E</i>, Mobilization of pCD40L by T<sub>FH</sub> and Th2 cells in response to PMA plus ionomycin. <i>F</i>, To obtain polyclonal Th2 cells, mice were sensitized with OVA/alum followed by intratracheal challenge with OVA/PBS. <i>G</i>, The gating strategy for Th2 cells (CD4<sup>+</sup>T1/ST2<sup>+</sup>) and non-Th2 cells in BALF. <i>H</i>, Mobilization of pCD40L by polyclonal Th2 and non-Th2 cells in response to PMA plus ionomycin. Data are representative of two to three independent experiments.</p

    In vivo-generated Th1 and T<sub>FH</sub> cells possess and mobilize pCD40L.

    No full text
    <p><i>A</i>, Generation of antigen-specific Th1 cells. LCMV-glycoprotein-specific, TCR-transgenic SMARTA CD4<sup>+</sup> T cells were recovered from LCMV-infected mice on day 8 post-infection. <i>B</i>, Gating strategy for SMARTA cells (VΞ±2<sup>+</sup>, VΞ²8.3<sup>+</sup>). <i>C</i>, Mobilization of pCD40L by SMARTA cells in response to PMA plus ionomycin or the LCMV peptide gp67-pulsed APC. <i>D</i>, Polyclonal Th1 and T<sub>FH</sub> cells. Spleen cells were obtained from LCMV-infected mice on day 12 post-infection. <i>E</i>, Gating strategy for T<sub>FH</sub> (CD4<sup>+</sup>CD44<sup>hi</sup>CXCR5<sup>hi</sup>PD-1<sup>hi</sup>) and Th1 (CD4<sup>+</sup>CD44<sup>hi</sup>CXCR5<sup>low</sup>PD-1<sup>low</sup>) cells. <i>F</i>, Mobilization of pCD40L by T<sub>FH</sub> and Th1 cells in response to PMA plus ionomycin. Data are representative of two independent experiments.</p
    corecore